Registry Measuring Impact of RNA Expression Testing on Treatment Decisions in Early Stage Lung Cancer and Assessing the Disease-free Survival With Long-term Follow-up (ONC006)
Stopped early
Conditions studied: Lung Cancer, NSCLC, NSCLC Adenocarcinoma
In brief
This registry is intended to measure the effect of myPlan Lung Cancer™ test has on influencing treatment decisions of Oncologists when added to standard clinical-pathological parameters in patients with early stage NSCLC. The sponsor is conducting two parallel registries, with one directed at Surgeons (ONC003) and the other at Oncologists (ONC006). This registry is specific to Oncologists (ONC006).
Key facts
- Study ID
- NCT02121899
- Run by
- Myriad Genetic Laboratories, Inc.
- People needed
- 44
- Starts
- 2015-04-01
- Expected to finish
- 2017-07-31
- Last updated by the study team
- 2017-09-05
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Diagnosis of early stage non-small cell lung adenocarcinoma
- Sub-population staging (IA, IB or IIA) as judged by the standard of practice at the investigational site
- Resection of tumor within previous 2 months of enrollment
- ECOG performance of 0-2
- A minimum life expectancy of six months
You may not qualify if…
- Previous myPlan Lung Cancer test performed
- Pre-operative radiation or chemotherapy for NSCLC
- Post-operative radiation or chemotherapy for NSCLC
- Enrollment in a separate clinical trial restricting treatment options
- Unable to provide informed consent
Where it is running
- Study site — Orlando, Florida, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.